This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Clinical Evaluation of the Sorin Group's REPLY MR-conditional Pacing System

This study has been withdrawn prior to enrollment.
Information provided by (Responsible Party):
LivaNova Identifier:
First received: April 1, 2011
Last updated: July 16, 2013
Last verified: July 2013
Permanent cardiac pacemakers have represented a contraindication to Magnetic Resonance Imaging (MRI). Strong static, gradient and radiofrequency fields used for MRI are thought to be detrimental to pacemaker function and possibly cause harm to patients undergoing MRI examinations. A previous study has shown that MRI is indicated in 17% of all patients with pacemakers within 12 months of device placement , which demonstrates the need of practical, safe approach for performing MRI on pacemaker patients. A new Reply MR-conditional pacing system is developed by Sorin Group for safe use in the MRI environment. The new pacing system is composed by the Reply pacemaker and the Filtrea bradycardia pacing leads. This study intends to demonstrate the safety and the efficacy in the MRI environment of the Sorin Group Reply MR-conditional pacing system.

Condition Intervention Phase
Dual-chamber Pacemaker Placement Procedure: MRI exam Procedure: control Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Clinical Evaluation of the Sorin Group's REPLY MR-conditional Pacing System

Further study details as provided by LivaNova:

Primary Outcome Measures:
  • assess the pacing system-, MRI- and implant procedure-related complication-free rate [ Time Frame: 1 month ]
  • assess atrial and ventricular lead-related complication-free rate [ Time Frame: 3 months ]
  • compare the changes in atrial and ventricular pacing thresholds before and after MRI, between MRI and control groups [ Time Frame: 3 months ]
  • compare the changes in atrial and ventricular sense amplitude after MRI between MRI and control groups [ Time Frame: 3 months ]

Secondary Outcome Measures:
  • Summarize all implant procedure, pacing system- and MRI procedure-related adverse events [ Time Frame: 12 months ]
  • Summarize atrial and ventricular electrical performances [ Time Frame: 3 months ]
  • Summarize atrial and ventricular lead handling [ Time Frame: 2 weeks ]

Enrollment: 0
Study Start Date: January 2012
Estimated Study Completion Date: May 2013
Estimated Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Control
Procedure: control
waiting room
Experimental: MRI
Procedure: MRI exam
MRI exam


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients who are candidates for dual-chamber pacemaker primo-implantation
  • Patients who have indication for implantation of a dual-chamber pacemaker according to the American College of Cardiology and the American Heart Association
  • Patients who are able and willing to undergo elective MRI scanning
  • Patients who are scheduled for implant of a Reply DR pacemaker and Filtrea lead(s) only
  • Patients who provided signed and dated informed consent

Exclusion Criteria:

  • Non MR-compatible device or material implant
  • Chronic atrial fibrillation (for atrial lead evaluation)
  • Incessant ventricular tachyarrhythmia (for ventricular lead evaluation)
  • Inability to understand the purpose of the study or refusal to co-operate
  • Unavailability for scheduled follow-ups at the implanting centre
  • Already included in another clinical study that could affect the results of this study
  • Inability or refusal to provide informed consent
  • Patient is minor (less than 18-year old)
  • Patient is pregnant (women of childbearing potential should have a negative pregnancy test prior to enrolment);
  • Patient has life expectancy of less than 1 year
  • Patient is forfeiture of freedom or under guardianship
  • Any patient to whom a contra-indication from device and lead labeling applies
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01341522

Sponsors and Collaborators
Principal Investigator: Francisco LEYVA, Dr Queen Elizabeth BIRMINGHAM UNITED KINGDOM
  More Information

Responsible Party: LivaNova Identifier: NCT01341522     History of Changes
Other Study ID Numbers: IBMR01 - REPLY MRI STUDY
Study First Received: April 1, 2011
Last Updated: July 16, 2013 processed this record on September 21, 2017